CoMind Raises Over $100 Million to Revolutionize Non-Invasive Brain Monitoring
- ByStartupStory | October 22, 2025
UK-based startup CoMind, dedicated to developing implant-free brain monitoring and treatment technology, has surpassed $100 million in total funding, including a $60 million Series A round led by Plural Ventures, a VC firm founded by Wise co-founder Taavet Hinrikus and other technology entrepreneurs.
Founded by James Dacombe at just 17, CoMind’s groundbreaking technology offers a non-invasive alternative to traditional brain monitoring methods that require drilling holes into patients’ skulls. This innovation promises to dramatically improve diagnosis and treatment for millions of patients suffering from traumatic brain injuries (TBIs) worldwide.
Tackling a Critical Medical Need
Each year in the United States, over 3 million people sustain traumatic brain injuries. However, only about 5% undergo intracranial pressure testing — a procedure requiring drilling into the skull and carrying a 15% complication rate. The remaining patients are often treated with insufficient data, leading to poorer outcomes and increased healthcare costs.
CoMind’s technology measures vital brain health indicators, such as cerebral blood flow, using advanced photonics-based sensors without needing invasive procedures. This innovation enables safer, more accurate, and affordable monitoring — a transformative leap in neurocritical care.
Ambitious Approvals and Product Expansion
The company aims to secure US FDA approval within two years, unlocking access to the vast intensive care unit (ICU) market. Beyond monitoring, CoMind plans to launch an AI-driven platform that converts sensor data into predictive insights, enabling earlier identification of complications and tailored treatment plans for brain injury patients.
Investor Confidence and Market Potential
Investors including Angelini Ventures, LocalGlobe, Octopus Ventures, Crane, Backed VC, and Entrepreneurs First have backed the startup’s vision and progress. LocalGlobe’s General Partner, Julia Hawkins, praised James Dacombe as a “generational founder,” highlighting the company’s potential to reshape brain health measurement through pioneering photonics technology.
Plural Ventures echoed this sentiment, stating that CoMind exemplifies breakthrough European science and engineering poised to create large-scale global impact with safer, more affordable medical alternatives.
The Future of Brain Monitoring and Treatment
CoMind’s technology heralds a new era for neurological care, replacing invasive and risky interventions with non-drill, precise, and continuous brain monitoring. This capability not only promises improved patient outcomes but also expands the market for brain health management tools worldwide.
As the company scales towards regulatory approvals and broader commercialization, CoMind is set to redefine how healthcare providers assess and treat critical brain conditions — offering hope and better care for millions.
Follow Startup Story
Related Posts
